Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 9.37
(-0.85%)
CNY 9.37
(-0.85%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.17 Billion CNY | 2.17% |
| 2022 | 2.13 Billion CNY | 6.57% |
| 2021 | 1.99 Billion CNY | 46.29% |
| 2020 | 1.36 Billion CNY | 4.45% |
| 2019 | 1.3 Billion CNY | 46.98% |
| 2018 | 890.47 Million CNY | 25.25% |
| 2017 | 710.93 Million CNY | 5.65% |
| 2016 | 672.94 Million CNY | -3.27% |
| 2015 | 695.66 Million CNY | 5.65% |
| 2014 | 658.48 Million CNY | -4.0% |
| 2013 | 685.9 Million CNY | 19.35% |
| 2012 | 574.71 Million CNY | 13.45% |
| 2011 | 506.58 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 683.4 Million CNY | 7.19% |
| 2024 Q3 | 469.65 Million CNY | -30.63% |
| 2024 Q1 | 637.57 Million CNY | 13.6% |
| 2023 Q3 | 547.02 Million CNY | 5.61% |
| 2023 Q4 | 561.23 Million CNY | 2.6% |
| 2023 FY | 2.17 Billion CNY | 2.17% |
| 2023 Q1 | 565.9 Million CNY | -24.96% |
| 2023 Q2 | 517.97 Million CNY | -8.47% |
| 2022 Q4 | 754.16 Million CNY | 73.53% |
| 2022 Q3 | 434.6 Million CNY | 2.22% |
| 2022 Q2 | 425.16 Million CNY | -17.81% |
| 2022 Q1 | 517.29 Million CNY | -24.95% |
| 2022 FY | 2.13 Billion CNY | 6.57% |
| 2021 Q3 | 455.54 Million CNY | -7.22% |
| 2021 FY | 1.99 Billion CNY | 46.29% |
| 2021 Q1 | 364.08 Million CNY | 13.54% |
| 2021 Q2 | 491.02 Million CNY | 34.87% |
| 2021 Q4 | 689.26 Million CNY | 51.3% |
| 2020 Q1 | 291.49 Million CNY | -9.78% |
| 2020 Q3 | 324.35 Million CNY | -24.67% |
| 2020 FY | 1.36 Billion CNY | 4.45% |
| 2020 Q2 | 430.56 Million CNY | 47.71% |
| 2020 Q4 | 320.67 Million CNY | -1.14% |
| 2019 Q2 | 341.58 Million CNY | 16.08% |
| 2019 FY | 1.3 Billion CNY | 46.98% |
| 2019 Q4 | 323.1 Million CNY | -7.65% |
| 2019 Q3 | 349.87 Million CNY | 2.43% |
| 2019 Q1 | 294.27 Million CNY | 14.83% |
| 2018 Q2 | 231.02 Million CNY | 17.25% |
| 2018 Q1 | 197.03 Million CNY | 23.67% |
| 2018 FY | 890.47 Million CNY | 25.25% |
| 2018 Q4 | 256.28 Million CNY | 24.33% |
| 2018 Q3 | 206.12 Million CNY | -10.78% |
| 2017 FY | 710.93 Million CNY | 5.65% |
| 2017 Q2 | 200.83 Million CNY | 2.33% |
| 2017 Q3 | 154.5 Million CNY | -23.07% |
| 2017 Q4 | 159.32 Million CNY | 3.12% |
| 2017 Q1 | 196.27 Million CNY | 22.29% |
| 2016 Q3 | 154.09 Million CNY | -17.75% |
| 2016 Q2 | 187.34 Million CNY | 9.56% |
| 2016 Q4 | 160.49 Million CNY | 4.15% |
| 2016 FY | 672.94 Million CNY | -3.27% |
| 2016 Q1 | 171 Million CNY | -15.96% |
| 2015 Q1 | 205.33 Million CNY | 3.39% |
| 2015 FY | 695.66 Million CNY | 5.65% |
| 2015 Q4 | 203.48 Million CNY | 57.74% |
| 2015 Q3 | 129 Million CNY | -18.27% |
| 2015 Q2 | 157.83 Million CNY | -23.13% |
| 2014 Q4 | 198.6 Million CNY | 0.0% |
| 2014 FY | 658.48 Million CNY | -4.0% |
| 2013 FY | 685.9 Million CNY | 19.35% |
| 2012 FY | 574.71 Million CNY | 13.45% |
| 2011 FY | 506.58 Million CNY | 0.0% |